British stocks opened largely unchanged on Monday, while European markets showed mixed trading, and the pound slipped against the U.S. dollar. As of 0720 GMT, the FTSE 100 edged down 0.02%, and the British pound fell 0.2% to just above $1.34. Germany’s DAX gained 0.05%, while France’s CAC 40 dropped 0.6%.
Aston Martin Lowers 2025 Volume Guidance
Aston Martin Lagonda Global Holdings PLC (LSE:AML) has cut its 2025 volume forecast, now expecting a mid-to-high single-digit percentage decline versus 2024. Weakening demand in North America and the Asia-Pacific region, coupled with ongoing tariff pressures, is weighing on performance. The automaker delivered around 1,430 wholesale units in Q3 2025, below last year’s 1,641 units and its prior guidance of broadly stable volumes.
Mondi Issues Profit Warning Amid Weak Demand
Mondi PLC (LSE:MNDI) has issued a profit warning after reporting weaker-than-expected Q3 results. Quarterly EBITDA fell to €223 million from €274 million in Q2. Excluding a €20 million forest fair value gain, EBITDA came in at €203 million, 15% below analyst forecasts. The packaging segments held steady, but the uncoated fine paper business underperformed, with challenging market conditions expected to continue through year-end.
Ferrexpo Increases Q3 Production
Ferrexpo PLC (LSE:FXPO) reported Q3 production of 1.51 million tonnes, up 3.3% from Q2 but down 29% from Q1 levels. The iron ore producer has limited operations to a single pellet line due to the ongoing suspension of VAT refunds by Ukrainian tax authorities, with withheld funds totaling $47 million.
AstraZeneca Breast Cancer Drug Shows Survival Benefit
In pharma news, AstraZeneca PLC (LSE:AZN) and Daiichi Sankyo’s Datroway demonstrated significant improvements in overall survival for metastatic triple-negative breast cancer patients ineligible for immunotherapy. The TROPION-Breast02 Phase III trial showed benefits in both overall survival and progression-free survival compared to chemotherapy, marking the first therapy to show a survival advantage in this patient population.
Shawbrook Group Announces London IPO
Shawbrook Group, a UK digital banking platform, confirmed plans for an initial public offering on the London Stock Exchange Main Market. The lender, which has grown its loan book from £1.4 billion in 2013 to £17.0 billion by June 2025, plans to issue new shares alongside existing shares sold by Marlin Bidco Limited.
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.
Leave a Reply